Á lódáil...
Managing toxicities of Bruton tyrosine kinase inhibitors
Inhibition of Bruton’s tyrosine kinase (BTK) has revolutionized the treatment landscape for patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal B-cell receptor signaling, BTK inhibitors (BTKis) impair cell proliferation, migration, and activation of NF-κB....
Na minha lista:
| Foilsithe in: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Main Authors: | , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
American Society of Hematology
2020
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7727553/ https://ncbi.nlm.nih.gov/pubmed/33275698 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000118 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|